Although this is, to our knowledge, the first study to demonstrate SLC1A1 protein and activity changes in drug-resistant cancer cells, altered SLC1A1 mRNA expression was also reported in ovarian cancer cells and in the NCI-60 cancer cell line panel [14, 15], suggesting a more widespread relevance than CRC. Here, SLC1A1 is linked to ovarian carcinoma.